Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
The Immunology of Hepatitis B Infection
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

The Immunology of Hepatitis B Infection

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 2424

Special Issue Editors

Dr. Seik-Soon Khor

E-Mail Website
Guest Editor
Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore, Singapore
Interests: HLA; GWAS; WGS, KIR, LILRA, COVID-19, hepatitis-B, SNPs
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Katsushi Tokunaga

E-Mail Website
Guest Editor
Genome Medical Science Project, National Center for Global Health and Medicine Hospital, Tokyo 162-8655, Japan
Interests: hepatitis; osteoarthritis; primary biliary cirrhosis; transcriptional regulation; autoimmune syndrome

Special Issue Information

Dear Colleagues,

Chronic hepatitis B and C account for 80% of all hepatocellular carcinoma (HCC) and most often occur in people with chronic liver diseases such as cirrhosis caused by hepatitis B or C. Hepatitis B virus (HBV) was first identified by Dr. Baruch Blumberg in 1965, and blood banks started to screen blood donations for hepatitis B in 1971. In 1975, the first heat-inactivated hepatitis B vaccine was developed by Dr. Blumberg and Dr. Irving Millman. HBV is a small, double-stranded DNA virus, and the serologic markers used to detect HBV infection include hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), immunoglobulin class G (IgG), immunoglobulin class M (IgM) antibodies to hepatitis B core antigen (IgM anti-HBc), and anti-HBc (IgG anti-HBc). Each of these markers represents the different phases of the viral infection. Genome-wide association studies of HBV-infected patients have identified several genetic markers such as HLA genes. These markers are useful in identifying patients who are prone to hepatitis B infection and patients at high risk of HCC progression and responses to hepatitis B vaccines. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: host genetic markers, viral genetic markers, hepatitis B vaccine efficacy, side effects of hepatitis B vaccination, hepatitis B viral strain variants, the immunology of hepatitis B infection, and population-based genome-wide association studies.

I look forward to receiving your contributions.

Dr. Seik-Soon Khor
Prof. Dr. Katsushi Tokunaga
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatitis B
  • HBV
  • hepatocellular carcinoma
  • HLA
  • genetic markers

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 2433 KiB  
Article
Prediction Model with HLA-A*33:03 Reveals Number of Days to Develop Liver Cancer from Blood Test
by Nao Nishida, Jun Ohashi, Goki Suda, Takehiro Chiyoda, Nobuharu Tamaki, Takahiro Tomiyama, Sachiko Ogasawara, Masaya Sugiyama, Yosuke Kawai, Seik-Soon Khor, Masao Nagasaki, Akihiro Fujimoto, Takayo Tsuchiura, Miyuki Ishikawa, Koichi Matsuda, Hirohisa Yano, Tomoharu Yoshizumi, Namiki Izumi, Kiyoshi Hasegawa, Naoya Sakamoto, Masashi Mizokami and Katsushi Tokunagaadd Show full author list remove Hide full author list
Int. J. Mol. Sci. 2023, 24(5), 4761; https://doi.org/10.3390/ijms24054761 - 1 Mar 2023
Viewed by 2107
Abstract
The development of liver cancer in patients with hepatitis B is a major problem, and several models have been reported to predict the development of liver cancer. However, no predictive model involving human genetic factors has been reported to date. For the items [...] Read more.
The development of liver cancer in patients with hepatitis B is a major problem, and several models have been reported to predict the development of liver cancer. However, no predictive model involving human genetic factors has been reported to date. For the items incorporated in the prediction model reported so far, we selected items that were significant in predicting liver carcinogenesis in Japanese patients with hepatitis B and constructed a prediction model of liver carcinogenesis by the Cox proportional hazard model with the addition of Human Leukocyte Antigen (HLA) genotypes. The model, which included four items—sex, age at the time of examination, alpha-fetoprotein level (log10AFP) and presence or absence of HLA-A*33:03—revealed an area under the receiver operating characteristic curve (AUROC) of 0.862 for HCC prediction within 1 year and an AUROC of 0.863 within 3 years. A 1000 repeated validation test resulted in a C-index of 0.75 or higher, or sensitivity of 0.70 or higher, indicating that this predictive model can distinguish those at high risk of developing liver cancer within a few years with high accuracy. The prediction model constructed in this study, which can distinguish between chronic hepatitis B patients who develop hepatocellular carcinoma (HCC) early and those who develop HCC late or not, is clinically meaningful. Full article
(This article belongs to the Special Issue The Immunology of Hepatitis B Infection)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop